HOME >> BIOLOGY >> NEWS
Shorter tuberculosis therapies could lead to substantial reductions in cases and deaths

Boston, MA -- New, shorter therapies to treat tuberculosis (TB), which kills millions worldwide each year, may make TB control efforts substantially more effective by simplifying treatment, improving patient outcomes and reducing transmission of new infections. Looking at the potential benefits if a two-month regimen becomes available during the next decade, a new study led by researchers at the Harvard School of Public Health (HSPH) reports that as many as 11 million cases and 5 million deaths could be averted through 2030 in the South-East Asia region alone, compared to a situation in which treatment continues at current levels with existing drug regimens. The research appears in the August 2006 online edition of Public Library of Science Medicine (www.plos.org).

Every year, some eight or nine million people develop active TB and some two million people die from the disease. The cornerstone of global control efforts is the World Health Organization's DOTS strategy, which relies on four or more drugs administered under the observation of health care workers for at least six months. No new first-line TB drugs have been developed in over 30 years, but recently an array of promising new drug candidates have been identified, which raises hopes that novel, shorter regimens may enter the TB treatment arsenal in the coming years.

Exploring a number of different scenarios, the researchers developed a mathematical model of TB to study what impact shortening treatment durations might have on the course of the epidemic. The results showed that shorter regimens could produce dramatic benefits at the population level by reducing patients' opportunities to default from treatment and therefore improving their own outcomes as well as curtailing transmission to others. Other possible indirect benefits were explored in alternative scenarios in which new regimens are accompanied by wider case detection, which might arise if sho
'"/>

Contact: Todd Datz
tdatz@hsph.harvard.edu
617-432-3952
Harvard School of Public Health
31-Jul-2006


Page: 1 2

Related biology news :

1. Shorter colds, milder flu may follow from newly revealed immune mechanism
2. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
3. Handicapping tuberculosis may be the way to a better vaccine
4. Developing a more effective vaccine for tuberculosis
5. Why is long-term therapy required to cure tuberculosis?
6. UA researchers identify new adherence factor, Pili, produced by tuberculosis
7. Pitt phage hunter takes on tuberculosis
8. Cost-effectiveness of treating multidrug-resistant tuberculosis
9. New potential drug target in tuberculosis
10. National Institutes of Health funds $13.7 million for Texas tuberculosis study
11. Einstein researchers find potential new drugs for tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2019)... ... ... Dr. David Greene , Founder and CEO of R3 Stem Cell, ... the Rescue, was produced by Award Winning filmmaker Dr. Elliott Haimoff. , In the ... safety of the procedures along with the potential for helping patients avoid potentially risky ...
(Date:5/21/2019)... , ... May 21, 2019 , ... At their May ... for Tissue Engineered Medical Products (TEMPs) of the American Society for Testing and ... . Gaining this approval was the next step in the company’s plan to ...
(Date:5/15/2019)... ... 15, 2019 , ... The conventional method for characterizing brain ... ultra-thin two-dimensional slices, placed on glass microscope slides and qualitatively evaluated after staining. ... the brain is a highly heterogenous and complex tissue that is challenging to ...
Breaking Biology News(10 mins):
(Date:4/18/2019)... ... 2019 , ... Taking a step closer to a “green” ... Worcester Polytechnic Institute (WPI) has developed a novel process using an unusual solvent ... other biofuels more economically. , Isobutanol, like ethanol, is an alcohol, but its ...
(Date:4/10/2019)... ... April 10, 2019 , ... ... have locked into multiple agreements to help companies advance their innovations to ... industry, ranging from synthetic biology companies that are gene editing therapeutic cells ...
(Date:4/8/2019)... JORDAN, Utah and BOSTON (PRWEB) , ... April ... ... in delivering cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch ... provides integration to an unprecedented range of business and contact-orientated applications while using ...
(Date:3/29/2019)... ... March 28, 2019 , ... ... milestones, CARB-X has proceeded with a second stage of funding for Specific’s Reveal™ ... which is on top of the $1.7 million already awarded by CARB-X. The ...
Breaking Biology Technology:
Cached News: